Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04251052 · ClinicalTrials.gov registry record · NA

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

A NA study of Ovarian Carcinoma, sponsored by NRG Oncology.

Recruiting
Registry status
NA
Development phase
1,956
Enrollment target
20
Study locations

NCT04251052 is a NA study of Ovarian Carcinoma that is actively recruiting participants, run by NRG Oncology. The registered enrollment target is 1,956 participants, below the 3,188-participant average among 35 other Ovarian Carcinoma trials with a reported enrollment target (39% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04251052, a NA study of Ovarian Carcinoma, is actively recruiting participants, sponsored by NRG Oncology.

RECRUITING
Registry status
NA
Development phase
1,956 participants
Enrollment target
20
Study locations

Study Summary

This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.

Conditions Studied

Interventions

  • PROCEDURE Biospecimen Collection
  • OTHER Quality-of-Life Assessment
  • PROCEDURE Magnetic Resonance Imaging
  • PROCEDURE Bilateral Salpingectomy
  • PROCEDURE Bilateral Salpingectomy with Oophorectomy

Study Locations (20)

California

  • Kaiser Permanente-Deer Valley Medical Center - Antioch
  • Tower Cancer Research Foundation - Beverly Hills
  • Keck Medicine of USC Buena Park - Buena Park
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
  • Mercy Cancer Center - Carmichael - Carmichael
  • Mercy San Juan Medical Center - Carmichael
  • City of Hope Comprehensive Cancer Center - Duarte
  • Kaiser Permanente Dublin - Dublin

Alaska

  • Anchorage Associates in Radiation Medicine - Anchorage
  • Anchorage Radiation Therapy Center - Anchorage
  • Alaska Breast Care and Surgery LLC - Anchorage
  • Alaska Oncology and Hematology LLC - Anchorage
  • Alaska Women's Cancer Care - Anchorage
  • Katmai Oncology Group - Anchorage
  • Providence Alaska Medical Center - Anchorage

Arizona

  • CTCA at Western Regional Medical Center - Goodyear
  • Banner University Medical Center - Tucson - Tucson
  • University of Arizona Cancer Center-North Campus - Tucson

Alabama

  • University of Alabama at Birmingham Cancer Center - Birmingham

Arkansas

  • University of Arkansas for Medical Sciences - Little Rock

Trial Details

FieldValue
Enrollment Target 1,956 participants
Start Date 2020-09-01
Est. Completion 2047-06-30
Phase NA

Sponsor

NRG Oncology

64 total trials

What the Registry Record Tells You About NCT04251052

The ClinicalTrials.gov registry entry for NCT04251052 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,956 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,188-participant average among 35 other Ovarian Carcinoma trials with a reported enrollment target (39% lower). The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ovarian Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT04251052 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alaska, Arizona.

Frequently Asked Questions

What is clinical trial NCT04251052 about?

NCT04251052 is a clinical study titled "A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer". This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpi...

What is the current status of trial NCT04251052?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,956 participants. The study started on 2020-09-01. Estimated completion is 2047-06-30.

What conditions does trial NCT04251052 study?

This clinical trial studies the following conditions: Ovarian Carcinoma.

What interventions are being tested in trial NCT04251052?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Quality-of-Life Assessment (OTHER), Magnetic Resonance Imaging (PROCEDURE), Bilateral Salpingectomy (PROCEDURE), Bilateral Salpingectomy with Oophorectomy (PROCEDURE).

Who is sponsoring clinical trial NCT04251052?

This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04251052 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ovarian Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.